A cluster of recent studies has sharpened the scientific picture of how T cells switch on, tracking the molecular signals ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
Peer-reviewed study demonstrates tumor-eradicating activity and durable anti-tumor immunity in multiple preclinical solid tumor models Findings ...
For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...
NCCN now recognizes BCG-unresponsive papillary-only NMIBC as eligible for nogapendekin plus BCG, broadening access beyond the ...
Engineers at the University of Pennsylvania have built a lipid nanoparticle that chemically fuses an IDO-pathway inhibitor with the very lipids that carry IL-12 mRNA into tumors, creating a single ...
A substantial proportion of patients with autoimmune diseases experienced a new side effect called local immune effector cell–associated toxicity syndromes (LICATS) after receiving chimeric antigen ...
CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...